1 domain / 2 areas / 1 specialization
Oppenheimer
Data updated
Oppenheimer & Co. Inc. is a global financial institution offering wealth management, capital markets, and investment banking services. Its institutional-facing businesses include equity research, investment banking, and institutional services, and its principal place of business is in New York, New York.
In the psychedelic ecosystem, Oppenheimer matters primarily as a generalist capital-markets and healthcare finance platform rather than a specialist psychedelic investor. Its healthcare research and investment banking coverage spans biotechnology, biopharmaceuticals, specialty pharmaceuticals, and emerging-growth companies, which can make it relevant to public and private life-sciences issuers that overlap with psychedelic drug development.
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.
Oppenheimer is best understood as a broad-market financial services firm with meaningful healthcare and biotechnology coverage, not a dedicated psychedelic investor. The firm supports companies through equity research, capital markets, and investment banking, including emerging-growth and life-sciences businesses, so its relevance to psychedelics is more likely to come through transactional or coverage activity than through a public thematic mandate.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
No Public Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Founded
- 1881
- HQ
- 85 Broad Street, New York, NY 10004, United States
- Website
- Visit